Invented by Richard Morgan, Kevin Friedman, 2Seventy Bio Inc

The market for BCMA chimeric antigen receptors (CARs) is rapidly growing in the field of cancer immunotherapy. BCMA is a protein that is expressed on the surface of multiple myeloma cells, making it an attractive target for CAR-T cell therapy. CAR-T cell therapy involves genetically modifying a patient’s own T cells to recognize and attack cancer cells. The market for BCMA CAR-T cell therapy is expected to grow significantly in the coming years. According to a report by Allied Market Research, the global CAR-T cell therapy market is expected to reach $8.61 billion by 2026, with BCMA CAR-T cell therapy being one of the key drivers of this growth. Several companies are currently developing BCMA CAR-T cell therapies, including Bluebird Bio, Juno Therapeutics, and Celgene. In March 2019, the FDA granted breakthrough therapy designation to Celgene’s BCMA CAR-T cell therapy, bb2121, for the treatment of relapsed and refractory multiple myeloma. The success of BCMA CAR-T cell therapy in clinical trials has also contributed to the growth of the market. In a phase 1 clinical trial of bb2121, 33 out of 35 patients with relapsed or refractory multiple myeloma responded to the treatment, with 15 achieving a complete response. However, there are still challenges to be addressed in the development of BCMA CAR-T cell therapy. One of the main challenges is the toxicity associated with the treatment, which can cause cytokine release syndrome and neurotoxicity. Researchers are working to develop strategies to mitigate these side effects. Another challenge is the high cost of CAR-T cell therapy, which can exceed $500,000 per patient. This has led to concerns about the affordability and accessibility of the treatment. Despite these challenges, the market for BCMA CAR-T cell therapy is expected to continue to grow as more companies enter the field and clinical trials continue to demonstrate the efficacy of the treatment. The development of BCMA CAR-T cell therapy represents a significant advancement in the field of cancer immunotherapy and has the potential to revolutionize the treatment of multiple myeloma.

The 2Seventy Bio Inc invention works as follows

The invention provides improved compositions to adoptive T-cell therapies for B-cell related conditions.

Background for Bcma chimeric antigen receptors

Technical Field

Description of Related Art



A. Overview

B. Definitions

C. Chimeric Antigen Receptors

D. Polypeptides

E. Polynucleotides

F. Viral vectors

G. Genetically modified cells

H. Compositions & Formulations

I. “I.


Example 1

Construction of Anti-BCMA Cars

Example 2

High Throughput Screen for Humanized Anti-BCMA CAR

Example 3

Antigen Specific Reactivity in CAR T Cells

Example 4

Click here to view the patent on Google Patents.